Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BioCryst Expands Management Team
BioCryst Appoints Industry Veterans to Two Newly Created Positions, Vice President, Strategic Planning and Commercialization and Executive Director, Oncology Development
BIRMINGHAM, Ala., April 2 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced it has expanded its management team with the appointment of industry veterans to two newly created positions. As part of the company's goal to add scientific expertise and corporate leadership, David S. McCullough has been named Vice President, Strategic Planning and Commercialization, and Philip P. Breitfeld, M.D., has been named Executive Director, Oncology Development and Associate Chief Medical Officer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGO )
'As our lead products enter late-stage clinical testing, BioCryst is focusing on growing its pharmaceutical development expertise,' said Jon P. Stonehouse, Chief Executive Officer of BioCryst. 'The addition of these two highly respected, seasoned pharmaceutical professionals to our management team will be invaluable as we drive towards commercialization and continue the development of products in our pipeline.'
David McCullough most recently served as Director, Global Corporate Development in the Ethical Pharmaceuticals Division at Merck KGaA in Darmstadt, Germany. In that position he was responsible for leading the company's efforts in evaluating the commercial value of specific product opportunities and in the case of the Serono SA acquisition, their entire company portfolio. Mr. McCullough led the commercial assessment of strategic and financial attractiveness of over 40 companies in oncology and other therapeutic areas. Prior to that position, Mr. McCullough was an integral part of the Business Operations and Market Research Team in the Oncology Business Unit of Eli Lilly and Company. David started his career in healthcare as a sales representative at Zeneca Pharmaceuticals. With nearly 20 years of healthcare business experience, Mr. McCullough brings with him a background which includes extensive marketing, sales, general business management and international experience. In this new position, Mr. McCullough will be responsible for leading the development of and updating BioCryst's strategic plan and establishing global marketing strategies. In addition, Mr. McCullough will be responsible for executing the company's commercial plans beginning with Fodosine(TM) and Peramivir.
'As we begin initial planning for commercialization, David McCullough's expertise and business acumen will add significant strength to our executive management team,' said Mr. Stonehouse. 'David brings a wealth of experience in life sciences business analysis, product marketing and pharmaceutical sales that will be essential elements of our success as we continue to advance our pipeline and key product candidates including Fodosine(TM) in oncology, peramivir in seasonal and life-threatening influenza and BCX-4208 in autoimmune diseases and transplantation.'
Mr. McCullough received his Bachelor of Science degree from Western Illinois University.
Prior to joining BioCryst, Dr. Breitfeld was Medical Director, Oncology at EMD Pharmaceuticals, Inc. a U.S. based, wholly owned subsidiary of Merck KGaA of Darmstadt, Germany. In that position Dr. Breitfeld's responsibilities included the clinical development strategy for global product teams, and the evaluation of the clinical potential of product opportunities. As a pediatric oncologist, Dr. Breitfeld has been a member of and has held scientific leadership positions in the Children's Oncology Group. He was a widely respected academician during a 20-year academic career and has had previous appointments at Duke University, Indiana University, the University of Massachusetts, and Harvard University.
'We are extremely pleased to have Phil Breitfeld join BioCryst and our Clinical Development Group. He has extensive experience in the treatment of patients with a variety of hematologic and oncologic diseases, and throughout his career has been intimately involved in the design of clinical investigations of therapies for these conditions,' said W. James Alexander, M.D., M.P.H., Senior Vice President, Clinical and Regulatory Operations and Chief Medical Officer. 'The BioCryst product pipeline provides many opportunities for Phil to make significant contributions to our development programs.'
Dr. Breitfeld received his A.B. in Chemistry from Princeton University and his M.D. from the University of Rochester, School of Medicine.
About BioCryst
BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In February 2007 BioCryst established a partnership with Shionogi & Co., to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the company's web site at http://www.biocryst.com.
Regulatory
BIOCRYST PHARMACEUTICALS INC - PRE 14A (Filed: 30-03-2007)
Sub Document 1
Page 1: UNITED STATES
Page 2: BIOCRYST PHARMACEUTICALS, INC.
Page 3: TABLE OF CONTENTS
Page 4: BIOCRYST PHARMACEUTICALS, INC.
Page 5: Required Votes, Abstentions, and Broker Non-Votes
Page 6: DIRECTORS WITH TERMS EXPIRING AT THE ANNUAL MEETING OF STOCKHOLDERS IN 2009
Page 7: J. Claude Bennett, M.D.
Page 8: Recommendation of the Board of Directors
Page 9: Eligibility
Page 10: Stock Appreciation Rights
Page 11: (cont'd)
Page 12: General Provisions
Page 13: Equity Compensation Plan Information
Page 14: Federal Income Tax Consequences
Page 15: Share Rights Awards
Page 16: (cont'd)
Page 17: Required Vote
Page 18: (cont'd)
Page 19: Corporate Governance and Nominating Committee
Page 20: Stockholder Communications
Page 21: Role of Compensation Consultants
Page 22: Short-Term Incentive Compensation
Page 23: Other Elements of Compensation
Page 24: Employment Agreements of Other Named Executive Officers
Page 25: Policy Regarding Tax Deductibility of Compensation
Page 26: GRANTS OF PLAN-BASED AWARDS
Page 27: OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2006
Page 28: 2006 OPTION EXERCISES AND STOCK VESTED
Page 29: 2006 DIRECTOR COMPENSATION
Page 30: Compensation Committee Interlocks and Insider Participation
Page 31: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
Page 32: SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Page 33: STOCKHOLDER PROPOSALS
Page 34: BIOCRYST PHARMACEUTICALS, INC.
Page 35: II. STRUCTURE OF THE PLAN
Page 36: IV. ELIGIBILITY
Page 37: V. STOCK SUBJECT TO THE PLAN
Page 38: (cont'd)
Page 39: ARTICLE TWO
Page 40: Term and Exercise of Options
Page 41: (cont'd)
Page 42: Service
Page 43: II. INCENTIVE OPTIONS
Page 44: not
Page 45: IV. STOCK APPRECIATION RIGHTS
Page 46: not
Page 47: ARTICLE THREE
Page 48: not
Page 49: II. CORPORATE TRANSACTION/CHANGE IN CONTROL
Page 50: ARTICLE FOUR
Page 51: Option Term
Page 52: Cessation of Board Service
Page 53: provided
Page 54: Take-Over Price
Page 55: ARTICLE FIVE
Page 56: provided
Page 57: (cont'd)
Page 58: THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.
Page 59: BIOCRYST PHARMACEUTICALS, INC.
Sub Document
http://app.quotemedia.com/quotetools/showFilingOutline.go?symbol=BCRX&name=BioCryst Pharmaceuticals Inc.&link=http%3A//quotemedia.10kwizard.com/contents.xml%3Fipage%3D4779972%26repo%3Dtenk
IHub warning site for pump and dumps:
http://www.investorshub.com/boards/board.asp?board_id=7707
CDYV-new today.
THE HOTTEST ALERT!!!
Campaign for: CDYV - Price: $0.089, 5 Day Target price: $0.425.
Short-Term Bullish. Insider Buying Alert.
MFIC CEO retires:
MFIC Corporation Announces Retirement of Irwin Gruverman as Chairman of the Board And CEO
Friday April 6, 3:42 pm ET
NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation ("MFIC" or the "Company") announced today that Irwin Gruverman, Chairman of the Board and Chief Executive Officer of MFIC, has announced that he is stepping down from the Chairmanship and CEO positions effective April 6, 2007.
ADVERTISEMENT
Mr. Gruverman, 74, founded the Company in 1982 and has continuously served as its Chairman of the Board, Chief Executive Officer and, for periods of time, its President. Mr. Gruverman will continue to serve as a director of the Company and will act as Chairman Emeritus and continue to serve the Company on a limited basis.
James N. Little, Ph.D., the Company's senior outside director will assume the duties of interim Chairman of the Board while the Company undertakes a search for a new Chief Executive Officer. Dr. Little has served as a Director of the Company since December 1995 and is currently an independent consultant to companies in the scientific instrumentation industry. Previously, Dr. Little was the President of Cetek Corporation, a biotechnology drug discovery company, and was a senior executive in several scientific instrumentation companies including Waters Corporation and Zymark Corporation (now part of Caliper Life Science).
Dr. Little commented, "Mr. Gruverman has long been at the forefront of applied nanotechnology, the benefits of which are only now beginning to be understood and realized. It was Irv's recognition of the critical importance of building equipment capable of creating nanoparticles that led to the formation of the Company in 1982. Since that time, and under his direction, MFIC's equipment has been adopted by hundreds of customers in the biotech, pharmaceutical, chemical/coatings, personal care and food industries seeking to create innovative products or to greatly improve the size and uniformity and functionality of a wide variety of existing products and formulations. Irv used his considerable technical knowledge, energy and tenacity to promote the benefits of what is now known as nanotechnology through particle size reduction via our proprietary Microfluidizer® processor systems. Moreover, it was Irv who spearheaded the development of MFIC's increasingly larger and more complex equipment and systems that have caused the Company to take a leading position in the products formulation arena. In the last decade, Irv has been a tireless crusader for the commercial establishment of Microfluidics Reactor Technology, which enables the creation of formulations at the nano level through the development of chemical reactor systems based on Microfluidics technology and products."
"Irv's dedication and outstanding contribution to the growth and success of the Company, and the advancements of nanomanufacturing and nanoscale products cannot be stressed enough" added Dr. Little.
"Having spent 25 years in my efforts at the Company, I am looking forward to pursuing some of my other interests and to seeing a new generation of management take the Company to the next level", stated Mr. Gruverman.
The Company is appreciative of Mr. Gruverman's contributions and wishes him the best.
About MFIC CORPORATION
MFIC Corporation, through its Microfluidics Division, provides patented and proprietary high performance Microfluidizer® materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. The equipment enables the manufacture and formulation of numerous nanomaterials and nanoscale products. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers. For more information please visit http://www.microfluidicscorp.com/
Contact:
MFIC Corporation
Robert P. Bruno, 617-969-5452
Fax 965-1213
President & COO
or
Jack M. Swig, 617-969-5452
Fax 965-1213
Investor Relations
info@mfics.com
--------------------------------------------------------------------------------
Source: MFIC Corporation
....I know NWOG laughs at most of the posts on this board. I can hear them now..." Silly Americans........."
Yep, I agree. They probably said "silly Americans, fell for that $$2.17 lie"!
Anyone else unable to forward bulk emails from Yahoo? I think the scammers have placed a bug there (my bulk only) so I am unable to forward to SEC,lol.
Just waiting for that perfect storm to uncover some gold the next week or so :)
Lucked out and got a few more today at 1.25
Kind of borders on illegal, does'nt it.
Japan finds 128 abnormal cases in Tamiflu probe Thu Apr 5, 2:03 AM ET
TOKYO (AFP) - More than 100 Japanese, mostly young children and teenagers, have behaved abnormally since taking the blockbuster flu drug Tamiflu and eight of them killed themselves, officials said Thursday.
ADVERTISEMENT
Health authorities in both Japan, the largest importer of Tamiflu, and the United States had previously ruled out dangers from taking the drug, which is manufactured by Swiss drug giant Roche.
But Japan decided to launch a fresh investigation after a spate of new deaths which led the government last month to issue an emergency order suspending the prescription of Tamiflu to young people.
As part of the new probe, the health ministry looked at 1,079 potential cases reported since 2001 and confirmed that 128 patients had behaved abnormally after taking Tamiflu, a ministry official said.
A total of 100 patients who acted strangely were 20 years old or younger, and 43 of them were under 10 years old, he said.
The behaviour included sudden fits of extreme behaviour such as trying to jump from a balcony, the official said.
Eight people -- five in their teens and three adults -- died after falling from tall buildings or in drastic actions such as running in front of a car, he said.
The report was submitted Wednesday to a health ministry panel which is investigating whether Tamiflu was to blame for the abnormal behaviour, he said.
Tokyo buys more than 60 percent of the world's supply of Tamiflu, which is prescribed for the common flu and is seen as a frontline drug against a potential avian influenza pandemic.
Roche denies any dangerous side-effects of its drug, which Japan has stockpiled as a precaution for such a pandemic.
CVM execs mentioned in last paragraph:
http://www.the-scientist.com/article/home/52982/
From a poster on another board who listened to CC:
By: mechgator
02 Apr 2007, 05:56 PM EDT
Msg. 11599 of 11605
Jump to msg. #
re: the conference call
From listening to the conference call, I also did not get the impression at all that 2007 will be bad, as many here seem to imply.
As you all know, Irv and the management, have historically been quite matter-of-factly and even conservative in the overall assessment.
He even stated that he himself does not even know what the actual final sales # for Q1 is gonna be since it just closed on Friday.
Irv repeatedly stated that this is a capital goods company, which translates into a potentially bumpy sales curve.
Looking for another IR firm to replace Kawoski (spelling). Finding a replacement is a prority
To be eligible for AMEX application, share has to be above $3 for 30 days. So at this stage, the company is not eligible yet.
Currently working with Umass/Lowell on three separate projects, although 'promising', it is still quite 'speculative' (I am quoting the words from Irv himself)
at this stage whether these will translate into successful ventures.
My take,
Overall, not a lot of positive news were reported, this added to the dissappointment of a missed quarter (altough fully explained by the management) and the reported
fact that Pfizer had unloaded its stake, contributed to the overall gloominess. IMHO the fact that Pfizer unloaded its stake (until Feb 07) should be a positive, which removed
a large overhang out of the stock (again words from Irv). I agree that the stock my not move much for a few months, but at this stage, a lot of bad news have already been priced into
the shares. While I am very dissappointed as everyone here, I will continue to add to my position. The story of this company is yet to be told.
(note: many of the longs had for a long time trumpeted the fact that Pfizer, had owned the said stake, which I always thought to be neutral or even slightly negative given the non-strategic
nature of its involvement. Irv himself stated today that Pfizer merely had its MFIC has an entry on its book, and never tried to contact the mgt about its intention about its stale)
Wow, no wonder SLJB selected them,lol,lol. Birds of feather flock together,lol.
Keep drinking that juice,lol.
Looks like this is the bad news causing the big drop-can't believe it.
MFIC Corporation Comments on Preliminary Revenues for the First Quarter of 2007
11:44a ET April 2, 2007 (Business Wire)
MFIC Corporation ("MFIC" or the "Company")(OTCBB: MFIC) announced today that it anticipates that revenues for the first quarter of 2007 will be significantly lower than the $3.2 million revenues posted in the first quarter of 2006. As a result of the lower first quarter 2007 revenues, the Company anticipates reporting a loss for the period. Delays in shipping of two production Microfluidizer processor systems, valued in the aggregate at approximately $644,000, is the primary reason for the lower revenue result. Final testing of one system in the last week of the quarter encountered a technical difficulty which could not be resolved quickly; the second delay was caused by issues regarding scheduling of the final testing process before the quarter's end. Both production units are anticipated to be booked as revenue in the second quarter of 2007.
As stated in prior filings and releases, capital goods manufacturers, such as MFIC, often experience uneven sequential quarterly revenues, and the December 31, 2006 and March 31, 2007 quarterly results are an example of this. Revenue recognition is dependent on a customer's acceptance of the equipment's performance. Delays in customer acceptance can significantly impact the amount of revenue recognized in a specific accounting period.
Order backlog as of March 31, 2007 was $2.9 million as compared to $3.5 million as of March 31, 2006 and $3.0 million as of December 31, 2006. Management remains optimistic regarding financial performance in 2007.
As previously announced, MFIC will hold an investor conference call beginning at 1:00 PM Eastern time on April 2, 2007. The domestic call in number is (800)370 0898 and the Conference I.D. number is 8634648. For those who cannot listen and participate in the live event, it is anticipated that a replay of the call will be available on the Company's website: www.mficcorp.com later this week.
FORWARD LOOKING STATEMENT:
I bet they reject the offer because pps is worth more than $2.17 per share :).
Taglich Brothers comments on MFIC's spectacular Q4 and Taglich's lowball estimates:
What's New
On March 29, 2007, MFIC Corporation (OTC BB: MFIC) reported results for its fourth quarter and fiscal year ended December 31, 2006 versus the same period in 2005.
For the quarter, the Company reported that revenues increased 64% to $5.0 million from $3.1 million. MFIC reported fourth quarter net income of $1.0 million or $0.10 per diluted share versus a net loss of $0.5 million or $(0.06) per share.
For fiscal 2006, the Company reported that revenues increased 34% to $15.7 million from $11.6 million. MFIC reported fiscal 2006 net income of $1.3 million or $0.12 per diluted share versus a net loss of $1.0 million or $(0.10) per share.
In comparison, Taglich Brothers’ estimates called for fourth quarter and fiscal 2006 revenues of $3.8 million and $14.4 million, respectively, and fourth quarter and fiscal 2006 net income of $0.1 million or $0.01 per diluted share and $0.4 million or $0.04 per diluted share, respectively.
So, shmoopy; did you just answer my question? Sell at $6 plus :).
Wow, just got home and checked TDA acct. and immediately knew news was good. Now, another problem-when do I sell,lol.
PPTM-new one
Are you aware of the Biggest wave Sweeping the Telecom
industry right now? It's called VOIP and it's taking the
sector by Storm. We are bringing you an Amazing Play that
is Right in the thick of the business.
This winner is Peopleline Telecom (PPTM). As with all tech
plays it's about catching that Rising Star on the ground
floor and Riding it up. PPTM is in just such a position.
PPTM opened Friday at 25 cents and moved up 20% to close at
30 cents on this news:
LOS ANGELES, March 27, 2007 (PRIME NEWSWIRE) --
Peopleline Telecom Inc. (Other OTC:PPTM.PK - News) announced today
yet another expansion to the Peopleline VoIP Network to service eastern Canada.
Monday brought news which Strongly Suggested that the Fair
market Value for PPTM shares is around $1.50, bringing on
another round of price Appreciation.
This is just an Opening Taste of what is to come. The
upcoming News and Promotion are going to see this one at
around $1.00 in no time!
Don't miss this sure winner!
Hellish alright-down 25% for day,lol.
It would be nice to see him thrown in jail by the SEC, but like you, I dont think it will happen. Lots of posters are saying he left himself open to charges.
At least the SEC has gotten off their duffs and started throwing a few pink scammers in jail along with some of the big boys.
Cramer confesses:
Extra3/23/2007 4:30 PM ET
Jim Cramer: Here's how to cheat
The popular CNBC host, a former hedge fund manager, could draw scrutiny from federal regulators after telling an interviewer about methods for manipulating the stock market.
Stock market commentator and CNBC television host Jim Cramer has raised eyebrows after describing illegal activities used by hedge fund managers to manipulate stock prices.
In a December video interview on the Web site of TheStreet.com (TSCM, news, msgs), a financial news company he co-founded, Cramer, while never saying he used such tactics himself, described how it was possible to push stocks higher or lower at his previous job running a hedge fund.
The interview, which has received widespread attention only after being posted to online video site YouTube, may be studied by government and stock market regulators, said hedge fund experts and legal sources.
Cramer: It's a fun, lucrative game
The interview described methods, including tactical buying, shorting and using options, to create an impression in the market that could prompt other traders and investors to buy or sell a stock.
"A lot of times when I was short at my hedge fund . . . meaning I needed (a stock) down, I would create a level of activity beforehand that could drive the futures," said Cramer. "It's a fun game and it's a lucrative game."
Cramer, host of the popular CNBC television show "Mad Money," described other tactics that could be used to drive down technology stocks such as Research in Motion (RIMM, news, msgs) or Apple (AAPL, news, msgs) to make them cheaper to purchase later. CNBC is owned by General Electric (GE, news, msgs).
In the interview, Cramer said a hedge fund manager's favorite tactic is to get a rumor about a stock to an unwitting reporter -- at The Wall Street Journal or at his current employer, CNBC -- and hope that it moves the stock in the direction the manager wants.
Cramer said some tactics are "blatantly illegal" but sometimes essential for poorly performing hedge funds.
Cramer said if a market participant wanted to get shares of a company like Research in Motion lower, then he should first get investors "talking about it as if there is something wrong with RIMM. Then you call the (Wall Street) Journal and get the bozo reporter in Research in Motion and you would feed that (rival) Palm's (PALM, news, msgs) got a killer it's going to give away," he said. "These are all the things that you must do on a day like today and if you're not doing it, maybe you shouldn't be in the game.
"It might cost me $15 million or $20 million to knock RIMM down but it would be fabulous because it would beleaguer all the moron longs who are also keying on Research in Motion," Cramer said.
He also said the Securities and Exchange Commission does not understand some illegal activity.
Challenging financial regulators?
Hedge fund lawyer Ron Geffner of Sadis & Goldberg called the interview a "somewhat surprising confession to make publicly, which definitely invites suspicion by regulators."
"Whether he violated the law is unclear," Geffner said. "That is dependent on his trading records. But it's clear that he seems to be challenging regulators to come and examine him."
A spokesman for the SEC declined to comment on whether the agency is looking at Cramer's comments. A decade ago Cramer faced an SEC investigation over a column he wrote for SmartMoney magazine that touted four stocks without disclosing his holdings in them. He was eventually cleared of wrongdoing, according to news reports.
Other legal experts criticized Cramer's comments for suggesting that stock manipulation is widespread among the growing legions of hedge funds, which are investment vehicles that typically trade much more actively and use more complex strategies than mutual funds.
"This makes it sound like everyone is doing it, and the reality is that most hedge funds are not engaged in this kind of manipulative behavior," said Laurel FitzPatrick, a hedge fund lawyer with Ropes & Gray.
Cramer could not be reached for comment following calls to both TheStreet.com and CNBC. Spokespeople for CNBC and TheStreet.com were unavailable for comment.
Cramer said in the interview that he would not make such comments on his CNBC show.
Cramer, who regularly gives opinions on stocks on his daily TV show, also said stock market movements are often unconnected to the fundamental qualities of the underlying company.
"Who cares about the fundamentals?" he said. "The great thing about the market is that it has nothing to do with the actual stocks."
This article was reported and written by Dane Hamilton for Reuters. Hamilton previously worked for TheStreet.com.
The crooks are slowly being exposed (and jailed) in pennyland AND big board stocks! SEC is finally getting the message so we should force the politicians to take more action. Now Cramer confesses:
Extra3/23/2007 4:30 PM ET
Jim Cramer: Here's how to cheat
The popular CNBC host, a former hedge fund manager, could draw scrutiny from federal regulators after telling an interviewer about methods for manipulating the stock market.
Stock market commentator and CNBC television host Jim Cramer has raised eyebrows after describing illegal activities used by hedge fund managers to manipulate stock prices.
In a December video interview on the Web site of TheStreet.com (TSCM, news, msgs), a financial news company he co-founded, Cramer, while never saying he used such tactics himself, described how it was possible to push stocks higher or lower at his previous job running a hedge fund.
The interview, which has received widespread attention only after being posted to online video site YouTube, may be studied by government and stock market regulators, said hedge fund experts and legal sources.
Cramer: It's a fun, lucrative game
The interview described methods, including tactical buying, shorting and using options, to create an impression in the market that could prompt other traders and investors to buy or sell a stock.
"A lot of times when I was short at my hedge fund . . . meaning I needed (a stock) down, I would create a level of activity beforehand that could drive the futures," said Cramer. "It's a fun game and it's a lucrative game."
Cramer, host of the popular CNBC television show "Mad Money," described other tactics that could be used to drive down technology stocks such as Research in Motion (RIMM, news, msgs) or Apple (AAPL, news, msgs) to make them cheaper to purchase later. CNBC is owned by General Electric (GE, news, msgs).
In the interview, Cramer said a hedge fund manager's favorite tactic is to get a rumor about a stock to an unwitting reporter -- at The Wall Street Journal or at his current employer, CNBC -- and hope that it moves the stock in the direction the manager wants.
Cramer said some tactics are "blatantly illegal" but sometimes essential for poorly performing hedge funds.
Cramer said if a market participant wanted to get shares of a company like Research in Motion lower, then he should first get investors "talking about it as if there is something wrong with RIMM. Then you call the (Wall Street) Journal and get the bozo reporter in Research in Motion and you would feed that (rival) Palm's (PALM, news, msgs) got a killer it's going to give away," he said. "These are all the things that you must do on a day like today and if you're not doing it, maybe you shouldn't be in the game.
"It might cost me $15 million or $20 million to knock RIMM down but it would be fabulous because it would beleaguer all the moron longs who are also keying on Research in Motion," Cramer said.
He also said the Securities and Exchange Commission does not understand some illegal activity.
Challenging financial regulators?
Hedge fund lawyer Ron Geffner of Sadis & Goldberg called the interview a "somewhat surprising confession to make publicly, which definitely invites suspicion by regulators."
"Whether he violated the law is unclear," Geffner said. "That is dependent on his trading records. But it's clear that he seems to be challenging regulators to come and examine him."
A spokesman for the SEC declined to comment on whether the agency is looking at Cramer's comments. A decade ago Cramer faced an SEC investigation over a column he wrote for SmartMoney magazine that touted four stocks without disclosing his holdings in them. He was eventually cleared of wrongdoing, according to news reports.
Other legal experts criticized Cramer's comments for suggesting that stock manipulation is widespread among the growing legions of hedge funds, which are investment vehicles that typically trade much more actively and use more complex strategies than mutual funds.
"This makes it sound like everyone is doing it, and the reality is that most hedge funds are not engaged in this kind of manipulative behavior," said Laurel FitzPatrick, a hedge fund lawyer with Ropes & Gray.
Cramer could not be reached for comment following calls to both TheStreet.com and CNBC. Spokespeople for CNBC and TheStreet.com were unavailable for comment.
Cramer said in the interview that he would not make such comments on his CNBC show.
Cramer, who regularly gives opinions on stocks on his daily TV show, also said stock market movements are often unconnected to the fundamental qualities of the underlying company.
"Who cares about the fundamentals?" he said. "The great thing about the market is that it has nothing to do with the actual stocks."
This article was reported and written by Dane Hamilton for Reuters. Hamilton previously worked for TheStreet.com.
Thanks to roger wilco for spiffing up the ibox-esp. the charts.
PPTM still pumping em out-
Are you aware of the Biggest wave Sweeping the Telecom industry right now?
It's called VOIP and it's taking the sector by storm.
We are bringing you an Amazing Play that is right in the thick of the business.
This winner is Peopleline Telecom (PPTM).
As with all tech plays it's about catching that
rising star on the ground floor and riding it up.
PPTM is in just such a position.
Trrading at 30 cents(+20%) with astounding news on the way,
this is one play you can't afford to miss!
The upcoming news and prromotion is going to see this one
at around $1.00 in no time!
Thanks roger and I just added you as asst. mod. I saw where the original mod had not posted since Jan '06 on any board so asked to be mod and inserted some info in ibox.
NUKE IRANIAN TERRORISTS NOW!!!!!
UK says 15 soldiers detained by Iranian navy
Ministry summons Iranian ambassador, seeks immediate return of troops
Please explain your interpretation josman-I still do not understand. TIA.
Newbies to penny stock games-check out the latest spam/scams before you jump in. Also beware of scammers on message boards too. SEC is working to throw some of them in jail but they just keep coming.
http://www.investorshub.com/boards/board.asp?board_id=7707
Unigene Announces Financial Results for Fourth Quarter and Year-End 2006 Revenue for Fourth Quarter Doubles to $3.4 Million
Monday March 19, 2007 08:00:40 EDT
FAIRFIELD, N.J., Mar 19, 2007 (BUSINESS WIRE) --
Unigene Laboratories, Inc. (OTCBB: UGNE) announced its financial results for December 31, 2006.
Revenue for the three months ended December 31, 2006, was $3,415,000 compared to $1,600,000 for the three months ended December 31, 2005, and $6,059,000 for the year ended December 31, 2006, compared to $14,276,000 for the year ended December 31, 2005. Revenue for all periods is primarily due to Fortical. Revenue from Fortical sales and royalties were $3,217,000 for the three months ended December 31, 2006, $1,510,000 for the three months ended September 30, 2006; $348,000 for the three months ended June 30, 2006 and $197,000 for the three months ended March 31, 2006.
Fortical royalties were $1,232,000 and $606,000 for the three months ended December 31, 2006 and 2005, respectively and $2,451,000 and $2,613,000 for the year ended December 31, 2006 and 2005, respectively. Fortical sales were $1,984,000 and $2,822,000, for the three months and year ended December 31, 2006, respectively. Fortical sales were $804,000 and $6,479,000 for the three months and year ended December 31, 2005, respectively.
Our net loss for the three months ended December 31, 2006, was $3,025,000, or $.03 per share, compared to a net loss of $2,653,000, or $.03 per share for the three months ended December 31, 2005. The three months ended December 31, 2006, includes $233,000 in expenses for non-cash stock option compensation.
Our net loss for the year ended December 31, 2006, was $11,784,000 or $.14 per share, compared to a net loss of $496,000, or $.01 per share, for the year ended December 31, 2005. The year ended December 31, 2006, includes $794,000 in expenses for non-cash stock option compensation, as well as an additional $331,000 in non-cash expenses related to our deferred compensation plan. As of December 31, 2006, we have approximately $1,000,000 in expenses for non-cash stock option compensation that remains to be recognized, primarily in 2007.
Total operating expenses were $6,599,000 for the three months ended December 31, 2006, an increase from $4,301,000 for the three months ended December 31, 2005.
Total operating expenses were $17,039,000 for the year ended December 31, 2006, an increase from $13,681,000 for the year ended December 31, 2005.
Our cash balance at December 31, 2006 was $3,357,000, a decrease of approximately $789,000 from December 31, 2005.
"The doubling of revenues for the fourth quarter of 2006, as compared to the third quarter, confirms that the process of "pull through" for Fortical(R) is complete," commented Dr. Warren Levy, President and CEO. "In combination with recent prescription trends, this suggests a positive direction for future revenues."
Following are highlights of 2006 accomplishments and new developments:
-- According to NDC, prescriptions for Fortical, the Company's first U.S. product that was launched in August 2005, grew to almost 83,000 units in January, 2007, reflecting 36% growth since December and a 35% market share.
-- According to IMS, total weekly prescriptions exceeded 20,000 for the week ending March 2nd for the first time in the product's history.
-- Total prescriptions have grown 62% in the 10 weeks ended March 2nd while new prescriptions increased more than 108% during the same period.
-- The Company has recently reported $8 million in expected payments from its partner Novartis. In February 2007, Nordic Bioscience, the development partner of Novartis, initiated a Phase III clinical study for osteoporosis with oral calcitonin, triggering a $5.5 million milestone payment. In January 2007, Unigene and Novartis entered into a new $2.5 million supply agreement with Novartis for a second osteoporosis peptide.
-- Our first clinical studies in China have been completed, and reports are being compiled in preparation for a meeting with the Chinese regulatory authorities to discuss registration of the injectable form of the product.
-- In February 2007, Unigene was awarded a $900,000 SBIR grant from a division of the NIH to fund the continuation of the Company's proprietary program to identify novel therapeutic peptide hormones. If successful, this could lead to significant strengthening of Unigene's already considerable intellectual property position.
-- In November 2006, we engaged leading clinicians from Johns Hopkins Medical School to consult on the Company's Site-Directed Bone Growth (SDBG) program. At the same time, Unigene acquired the rights to three patent applications involving the use of equipment and procedures to expand our patent position. Although the research program is at an early stage, it may find application for the prevention and treatment of vertebral compression fractures, the prevention and treatment of hip fractures, the treatment of certain long bone fractures and possibly even the treatment of chronic back pain. According to a marketing consulting group, the number of Americans who had such medical procedures last year, or would have been candidates for the SDBG procedure had it been available, totaled 6.5 million potential patients. The Company plans to develop additional animal and possibly human data in 2007.
-- In March 2006, Unigene successfully completed a private placement, raising $13 million from an institutional investor.
-- When the Company's financial position permits, we intend to pay back related-party debt and eliminate the going concern uncertainty, to allow for listing of the common stock on a national exchange.
http://new.quote.com/stocks/story.action?id=BIZ078b6398
Unigene's Site-Directed Bone Growth Technology May Have Multiple Large Market Applications According to New Market Analysis
Tuesday March 20, 2007 08:31:28 EDT
FAIRFIELD, N.J., Mar 20, 2007 (BUSINESS WIRE) --
The site-directed bone growth (SDBG) technology currently being developed by Unigene Laboratories, Inc. (OTCBB: UGNE) in conjunction with Yale University may have the potential to provide clinicians with new techniques to target bone growth at the site of a fracture or at sites that are highly susceptible to fracture. This promising early-stage technology is currently being studied in animals. Unigene has identified several possible applications of this technology, each with substantial commercial potential.
The technology, which involves a minimally invasive surgical procedure in conjunction with the administration of one or more biologic agents, including a systemic anabolic agent produced by Unigene, was the subject of a detailed market analysis performed by a leading consulting group which specializes in the pharmaceutical sector. The study evaluates several clinical areas where this technology could have significant utility:
Spine
-- Treatment and Prevention of Vertebral Compression Fractures (2004 worldwide device market for spine - $3.5 billion)
-- Treatment - (2006 U.S. incidence - 800,000). SDBG could
be performed as an alternative to the use of current
cements in certain spinal stabilization procedures,
such as vertebroplasty/kyphoplasty, which do not foster
bone integration or growth. -- SDBG could be used in conjunction with standard
vertebroplasty to protect adjacent vertebrae from
subsequent compression fractures. -- Prevention - in patients who are severely osteoporotic
(2006 U.S. incidence - 430,000), the physician could
target vertebrae deemed susceptible to future
fractures.-- Treatment of Chronic Back Pain (2006 U.S. market for chronic back pain surgery - $5 billion, with 5 million surgical candidates)
-- SDBG could be used to replace more invasive surgical
procedures, including spinal fusion and diskectomy. -- Vertebral instability has been identified by leading
clinicians as a possible contributing factor in chronic
back pain. Targeting specific vertebrae and stimulating
new bone synthesis may result in a more stable
vertebrae with a subsequent reduction in bone pain.Hip
-- Treatment of hip fractures (2003 U.S. surgical admissions for hip fractures - 310,000). SDBG may be useful in improving the healing process and clinical outcome.
-- Prevention of hip fractures - in patients who are severely osteoporotic (2006 U.S. incidence - 430,000), SDBG may be useful in preventing future hip fractures by specifically increasing bone mineral density at a hip deemed susceptible to future fracture.
Long Bone
-- SDBG may be useful in improving the clinical outcome for non-union long bone fractures due to trauma and reducing patient recovery times (2006 U.S. incidence - 390,000). The technology may also reduce the occurrence of subsequent fractures.
"The results of the market analysis support Unigene's commitment to this program and its potential application to reducing the costs associated with the treatment of debilitating bone disorders," stated Dr. James Gilligan, Vice President of Product Development. "In addition, the feedback from interviews with clinical leaders in the field suggests that this technology is truly unique and may have the potential to revolutionize treatments for osteoporotic bone disease and fractures."
About Unigene
Unigene Laboratories, Inc. is a biopharmaceutical company focusing on the oral and nasal delivery of large-market peptide drugs. Due to the size of the worldwide osteoporosis market, Unigene is targeting its initial efforts on developing calcitonin and PTH-based therapies. Fortical(R), Unigene's nasal calcitonin product for the treatment of postmenopausal osteoporosis, received FDA approval and was launched in August 2005. Unigene has licensed the U.S. rights for Fortical to Upsher-Smith Laboratories, worldwide rights for its oral PTH technology to GlaxoSmithKline and worldwide rights for its calcitonin manufacturing technology to Novartis. The Company is also manufacturing a second peptide for Novartis. Unigene's patented oral delivery technology has successfully delivered, in preclinical and/or clinical trials, various peptides including calcitonin, PTH and insulin. Unigene's patented manufacturing technology is designed to cost-effectively produce peptides in quantities sufficient to support their worldwide commercialization as oral or nasal therapeutics. For more information about Unigene, call (973) 882-0860 or visit www.unigene.com. For information about Fortical, visit www.fortical.com.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements regarding us and our business, financial condition, results of operations and prospects. Such forward-looking statements include those which express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. We have based these forward-looking statements on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include statements about the following: general economic and business conditions, our financial condition, competition, our dependence on other companies to commercialize, manufacture and sell products using our technologies, the uncertainty of results of animal and human testing, the risk of product liability and liability for human trials, our dependence on patents and other proprietary rights, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, the failure to obtain regulatory approvals for our products and other risk factors discussed in our Securities and Exchange Commission filings. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various risk factors.
SOURCE: Unigene Laboratories, Inc.
Investor:
The Investor Relations Group
Daniel Berg/Dian Griesel, Ph.D.
212-825-3210
or
Media:
Janet Vazquez/Lynn Granito
212-825-3210
Copyright Business Wire 2007
Unigene Announces Financial Results for Fourth Quarter and Year-End 2006 Revenue for Fourth Quarter Doubles to $3.4 Million
Monday March 19, 2007 08:00:40 EDT
FAIRFIELD, N.J., Mar 19, 2007 (BUSINESS WIRE) --
Unigene Laboratories, Inc. (OTCBB: UGNE) announced its financial results for December 31, 2006.
Revenue for the three months ended December 31, 2006, was $3,415,000 compared to $1,600,000 for the three months ended December 31, 2005, and $6,059,000 for the year ended December 31, 2006, compared to $14,276,000 for the year ended December 31, 2005. Revenue for all periods is primarily due to Fortical. Revenue from Fortical sales and royalties were $3,217,000 for the three months ended December 31, 2006, $1,510,000 for the three months ended September 30, 2006; $348,000 for the three months ended June 30, 2006 and $197,000 for the three months ended March 31, 2006.
Fortical royalties were $1,232,000 and $606,000 for the three months ended December 31, 2006 and 2005, respectively and $2,451,000 and $2,613,000 for the year ended December 31, 2006 and 2005, respectively. Fortical sales were $1,984,000 and $2,822,000, for the three months and year ended December 31, 2006, respectively. Fortical sales were $804,000 and $6,479,000 for the three months and year ended December 31, 2005, respectively.
Our net loss for the three months ended December 31, 2006, was $3,025,000, or $.03 per share, compared to a net loss of $2,653,000, or $.03 per share for the three months ended December 31, 2005. The three months ended December 31, 2006, includes $233,000 in expenses for non-cash stock option compensation.
Our net loss for the year ended December 31, 2006, was $11,784,000 or $.14 per share, compared to a net loss of $496,000, or $.01 per share, for the year ended December 31, 2005. The year ended December 31, 2006, includes $794,000 in expenses for non-cash stock option compensation, as well as an additional $331,000 in non-cash expenses related to our deferred compensation plan. As of December 31, 2006, we have approximately $1,000,000 in expenses for non-cash stock option compensation that remains to be recognized, primarily in 2007.
Total operating expenses were $6,599,000 for the three months ended December 31, 2006, an increase from $4,301,000 for the three months ended December 31, 2005.
Total operating expenses were $17,039,000 for the year ended December 31, 2006, an increase from $13,681,000 for the year ended December 31, 2005.
Our cash balance at December 31, 2006 was $3,357,000, a decrease of approximately $789,000 from December 31, 2005.
"The doubling of revenues for the fourth quarter of 2006, as compared to the third quarter, confirms that the process of "pull through" for Fortical(R) is complete," commented Dr. Warren Levy, President and CEO. "In combination with recent prescription trends, this suggests a positive direction for future revenues."
Following are highlights of 2006 accomplishments and new developments:
-- According to NDC, prescriptions for Fortical, the Company's first U.S. product that was launched in August 2005, grew to almost 83,000 units in January, 2007, reflecting 36% growth since December and a 35% market share.
-- According to IMS, total weekly prescriptions exceeded 20,000 for the week ending March 2nd for the first time in the product's history.
-- Total prescriptions have grown 62% in the 10 weeks ended March 2nd while new prescriptions increased more than 108% during the same period.
-- The Company has recently reported $8 million in expected payments from its partner Novartis. In February 2007, Nordic Bioscience, the development partner of Novartis, initiated a Phase III clinical study for osteoporosis with oral calcitonin, triggering a $5.5 million milestone payment. In January 2007, Unigene and Novartis entered into a new $2.5 million supply agreement with Novartis for a second osteoporosis peptide.
-- Our first clinical studies in China have been completed, and reports are being compiled in preparation for a meeting with the Chinese regulatory authorities to discuss registration of the injectable form of the product.
-- In February 2007, Unigene was awarded a $900,000 SBIR grant from a division of the NIH to fund the continuation of the Company's proprietary program to identify novel therapeutic peptide hormones. If successful, this could lead to significant strengthening of Unigene's already considerable intellectual property position.
-- In November 2006, we engaged leading clinicians from Johns Hopkins Medical School to consult on the Company's Site-Directed Bone Growth (SDBG) program. At the same time, Unigene acquired the rights to three patent applications involving the use of equipment and procedures to expand our patent position. Although the research program is at an early stage, it may find application for the prevention and treatment of vertebral compression fractures, the prevention and treatment of hip fractures, the treatment of certain long bone fractures and possibly even the treatment of chronic back pain. According to a marketing consulting group, the number of Americans who had such medical procedures last year, or would have been candidates for the SDBG procedure had it been available, totaled 6.5 million potential patients. The Company plans to develop additional animal and possibly human data in 2007.
-- In March 2006, Unigene successfully completed a private placement, raising $13 million from an institutional investor.
-- When the Company's financial position permits, we intend to pay back related-party debt and eliminate the going concern uncertainty, to allow for listing of the common stock on a national exchange.
http://new.quote.com/stocks/story.action?id=BIZ078b6398
Perhaps in your mailbox but not mine. BTOD/HXPN in this mornings mail.
Great-thanks.
More info on Bird Flu Summit:
http://www.thejakartapost.com/detailgeneral.asp?fileid=20070317125725&irec=4
GTAP new one this afternoon came straight in by itself,lol.
lol-I think its still march of '06
SEC & FBI finally getting off their buFFs and throwing these POS pink scammers in jail. They are also going after scammers on message boards too. Below is post from another board re penny crooks:
Posted by: fmi81
In reply to: None Date:3/16/2007 8:48:59 AM
Post #of 35538
WARNING: "TO ALL PINKS" FORWARD LOOKING STATEMENTS WONT COVER LIES AND SAVE YOU FROM JAILTIME................................................................................................................................
CKYS Cyberkey officers arrested for lying to shareholders. Twelve companies halted for spamming campaigns that in essence lie to shareholders. Looks as if the authorities are cracking down on Pink sheet companies with an agenda other than producing what they claim. The best is the FBI is arresting people in this process, I hope all pinks see this as a warning...The Wild West is getting some law and order and the Sheriffs name is FBI.
The days of claiming naked shorting while selling stock into runs looks as if it will have legal repercussions. The days of exaggerated PR'S to pump the stock price to sell shares while claiming market manipulation looks as if it will now get ya' jail time. Wow, looks like complaints made by shareholders may actually be acted upon by the SEC and FBI.
I am looking forward to being off the Pink sheets and on the OTCQX by May. PBLS has promised a move to a larger exchange, share structure explanation, financial's and other items that made many purchase shares of stock within the company. I am certain that PBLS will follow through on its public claims made through PR's and phone contacts with shareholders but, I am also very excited to see we as shareholders are getting some solid recourse in the event of a failure to follow through....
4/13?